{"doi":"10.17615/20da-6168","title":"Outcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort †: Outcomes of LDLT and DDLT Recipients With HCC","abstract":"Hepatocellular carcinoma (HCC) represents an increasing fraction of liver transplant indications; the role of living donor liver transplant (LDLT) remains unclear. Recurrence and post-transplant mortality rates were compared in LDLT and deceased donor liver transplant (DDLT) patients with at least one potential living donor evaluated. HCC recurrence and post-transplant mortality were evaluated among 100 LDLT and 97 DDLT recipients in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study. Mortality from date of evaluation of each recipient’s first potential living donor was analyzed. LDLT recipients had shorter time to transplant, were more likely to have tumors exceeding Milan criteria, higher alpha-fetoprotein levels, and less likely to have received pre-operative loco-regional therapy than DDLT recipients. Unadjusted 5-year HCC recurrence was significantly higher after LDLT (38%) than DDLT (11%), (p=0.0004). After adjustment for tumor characteristics, HCC recurrence remained significantly different between LDLT and DDLT recipients (hazard ratio (HR) = 2.35; p=0.04) for the overall cohort but not for recipients transplanted following the introduction of MELD prioritization. Five-year post-transplant survival was similar in LDLT and DDLT recipients from time of transplant (HR=1.32; p=0.27) and from date of LDLT evaluation (HR=0.73; p=0.36). We conclude that the higher recurrence observed after LDLT is likely due to differences in tumor characteristics, pre-transplant HCC management, and waiting time.","journal":"UNC Libraries","year":2020,"id":136205,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9408,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":595152,"name":"A. S. F. Lok","orcid":null,"position":1,"is_corresponding":false},{"id":595153,"name":"L. M. Kulik","orcid":null,"position":2,"is_corresponding":false},{"id":595154,"name":"P. H. Hayashi","orcid":null,"position":3,"is_corresponding":false},{"id":595155,"name":"Jessie Hong","orcid":null,"position":4,"is_corresponding":false},{"id":595156,"name":"C. E. Freise","orcid":null,"position":5,"is_corresponding":false},{"id":90360,"name":"R. A. FISHER","orcid":null,"position":6,"is_corresponding":false},{"id":595157,"name":"D. R. Rodrigo","orcid":null,"position":7,"is_corresponding":false},{"id":595158,"name":"J. E. Everhart","orcid":null,"position":8,"is_corresponding":false},{"id":595159,"name":"C. L. Berg","orcid":null,"position":9,"is_corresponding":false},{"id":595160,"name":"R. S. Brown","orcid":null,"position":10,"is_corresponding":false},{"id":589039,"name":"A. Shaked","orcid":null,"position":11,"is_corresponding":false},{"id":595151,"name":"G. T. Everson","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:16:48.793683Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}